SCHEMBL4353668

SCHEMBL4353668

Oc1c(Cl)cccc1NC(=S)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.54
▸ ALDH1A1 P00352 7/20 0.52
▸ MAPT P10636 6/20 0.52
▸ NPSR1 Q6W5P4 2/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.52
▸ KMT2A Q03164 5/20 0.51
▸ MEN1 O00255 4/20 0.51
▸ CYP1A2 P05177 2/20 0.51
▸ CYP3A4 P08684 2/20 0.51
▸ CYP2D6 P10635 2/20 0.51
▸ CYP2C19 P33261 2/20 0.51
▸ POLB P06746 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ XBP1 P17861 1/20 0.51
▸ LMNA P02545 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ GAA P10253 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6226175 0.87 SMN1; SMN2 (0.69) MAPK1ALDH1A1MAPTNPSR1KMT2A
SCHEMBL4348052 0.84 KMT2A (0.51) MAPK1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4343802 0.84 MAPK1 (0.56) MAPK1ALDH1A1MAPTKMT2ALMNA
SCHEMBL4351128 0.83 EPHX2 (0.61) MAPTKMT2AMEN1LMNAHTT
SCHEMBL6230061 0.83 KMT2A (0.67) MAPK1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4354217 0.82 MAPT (0.53) ALDH1A1MAPTNPSR1L3MBTL1KMT2A
SCHEMBL4347312 0.82 ALDH1A1 (0.58) MAPK1ALDH1A1MAPTKMT2AMEN1
SCHEMBL4347495 0.82 MEN1 (0.60) ALDH1A1MAPTNPSR1L3MBTL1KMT2A
SCHEMBL4346886 0.80 KMT2A (0.63) ALDH1A1MAPTNPSR1KMT2ACYP1A2
SCHEMBL4359457 0.80 MAPT (0.57) ALDH1A1MAPTNPSR1L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 — — US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 — — CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 — — EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 — — US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 — — CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 MAPK1 2517/4885ALDH1A1 2565/4885MAPT 4439/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 MAPK1 1913/4885ALDH1A1 2767/4885MAPT 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback